Abbott Laboratories、合併資產負債表結構:資產(季度數據)
|
|
2025年6月30日 |
|
2025年3月31日 |
|
2024年12月31日 |
|
2024年9月30日 |
|
2024年6月30日 |
|
2024年3月31日 |
|
2023年12月31日 |
|
2023年9月30日 |
|
2023年6月30日 |
|
2023年3月31日 |
|
2022年12月31日 |
|
2022年9月30日 |
|
2022年6月30日 |
|
2022年3月31日 |
|
2021年12月31日 |
|
2021年9月30日 |
|
2021年6月30日 |
|
2021年3月31日 |
|
2020年12月31日 |
|
2020年9月30日 |
|
2020年6月30日 |
|
2020年3月31日 |
|
|
現金和現金等價物 |
8.28% | |
8.02% | |
9.35% | |
10.16% | |
9.57% | |
8.67% | |
9.42% | |
9.31% | |
10.68% | |
12.41% | |
13.28% | |
13.18% | |
12.04% | |
10.37% | |
13.03% | |
12.61% | |
11.82% | |
11.07% | |
9.43% | |
6.49% | |
6.93% | |
5.06% | |
|
短期投資 |
0.39% | |
0.38% | |
0.43% | |
0.31% | |
0.32% | |
0.51% | |
0.52% | |
0.47% | |
0.44% | |
0.50% | |
0.39% | |
0.43% | |
0.48% | |
0.65% | |
0.60% | |
0.53% | |
0.39% | |
0.44% | |
0.43% | |
0.36% | |
0.40% | |
0.44% | |
|
貿易應收賬款,減去備抵 |
9.49% | |
9.00% | |
8.51% | |
9.48% | |
9.39% | |
9.11% | |
8.97% | |
9.02% | |
8.41% | |
8.16% | |
8.35% | |
8.80% | |
9.70% | |
9.70% | |
8.63% | |
8.68% | |
8.34% | |
8.38% | |
8.84% | |
8.18% | |
7.47% | |
7.92% | |
|
成品 |
5.14% | |
4.99% | |
4.54% | |
5.61% | |
5.56% | |
5.61% | |
5.39% | |
5.34% | |
5.46% | |
5.34% | |
5.11% | |
4.68% | |
4.81% | |
4.69% | |
4.10% | |
4.13% | |
4.26% | |
4.42% | |
4.18% | |
4.60% | |
4.71% | |
4.30% | |
|
正在進行的工作 |
1.15% | |
1.09% | |
1.03% | |
1.18% | |
1.21% | |
1.22% | |
1.10% | |
1.23% | |
1.15% | |
1.09% | |
0.91% | |
1.00% | |
0.96% | |
0.94% | |
0.92% | |
0.96% | |
1.09% | |
1.06% | |
0.98% | |
1.04% | |
0.98% | |
0.92% | |
|
材料 |
1.99% | |
2.07% | |
2.03% | |
2.37% | |
2.57% | |
2.60% | |
2.48% | |
2.66% | |
2.76% | |
2.61% | |
2.27% | |
2.20% | |
2.18% | |
2.06% | |
1.84% | |
2.04% | |
2.08% | |
1.92% | |
1.75% | |
1.82% | |
1.87% | |
1.62% | |
|
庫存 |
8.28% |
|
8.15% |
|
7.61% |
|
9.16% |
|
9.33% |
|
9.42% |
|
8.97% |
|
9.22% |
|
9.37% |
|
9.04% |
|
8.29% |
|
7.88% |
|
7.95% |
|
7.69% |
|
6.86% |
|
7.13% |
|
7.42% |
|
7.40% |
|
6.91% |
|
7.46% |
|
7.56% |
|
6.84% |
|
|
預付費用和其他應收款 |
2.69% | |
2.88% | |
3.16% | |
2.89% | |
3.06% | |
3.16% | |
3.08% | |
3.42% | |
3.15% | |
2.92% | |
3.58% | |
3.84% | |
3.46% | |
3.24% | |
3.12% | |
2.89% | |
2.91% | |
2.70% | |
2.57% | |
2.69% | |
2.68% | |
2.95% | |
|
流動資產 |
29.13% |
|
28.43% |
|
29.06% |
|
32.01% |
|
31.66% |
|
30.88% |
|
30.96% |
|
31.44% |
|
32.04% |
|
33.03% |
|
33.89% |
|
34.13% |
|
33.63% |
|
31.66% |
|
32.23% |
|
31.83% |
|
30.88% |
|
29.97% |
|
28.18% |
|
25.19% |
|
25.04% |
|
23.21% |
|
|
投資 |
1.14% | |
1.11% | |
1.09% | |
1.23% | |
1.20% | |
1.13% | |
1.09% | |
1.09% | |
1.09% | |
1.05% | |
1.03% | |
1.05% | |
0.99% | |
1.03% | |
1.09% | |
1.10% | |
1.10% | |
1.14% | |
1.13% | |
1.16% | |
1.13% | |
1.18% | |
|
不動產和設備,按成本計算 |
29.13% | |
28.75% | |
27.93% | |
30.74% | |
30.21% | |
30.43% | |
29.96% | |
29.28% | |
28.53% | |
27.92% | |
27.15% | |
26.52% | |
26.22% | |
26.38% | |
25.75% | |
25.99% | |
26.03% | |
25.69% | |
25.90% | |
26.03% | |
25.26% | |
25.02% | |
|
累計折舊和攤銷 |
-15.57% | |
-15.33% | |
-14.84% | |
-16.46% | |
-16.20% | |
-16.49% | |
-16.09% | |
-16.03% | |
-15.65% | |
-15.34% | |
-14.84% | |
-14.58% | |
-14.34% | |
-14.34% | |
-13.84% | |
-14.03% | |
-14.00% | |
-13.55% | |
-13.46% | |
-13.55% | |
-13.13% | |
-13.18% | |
|
淨財產和設備 |
13.57% |
|
13.42% |
|
13.09% |
|
14.28% |
|
14.01% |
|
13.95% |
|
13.87% |
|
13.25% |
|
12.88% |
|
12.58% |
|
12.31% |
|
11.94% |
|
11.88% |
|
12.04% |
|
11.91% |
|
11.97% |
|
12.03% |
|
12.13% |
|
12.45% |
|
12.48% |
|
12.13% |
|
11.84% |
|
|
無形資產,扣除攤銷后 |
7.05% | |
7.69% | |
8.16% | |
9.89% | |
10.72% | |
11.45% | |
12.04% | |
12.88% | |
13.41% | |
13.56% | |
14.04% | |
14.90% | |
15.62% | |
16.52% | |
16.94% | |
18.04% | |
18.67% | |
19.48% | |
20.38% | |
22.03% | |
22.95% | |
24.36% | |
|
善意 |
28.51% | |
28.68% | |
28.38% | |
31.82% | |
31.92% | |
32.27% | |
32.34% | |
32.29% | |
31.71% | |
31.07% | |
30.63% | |
30.61% | |
30.65% | |
31.32% | |
30.89% | |
31.57% | |
32.05% | |
32.13% | |
32.73% | |
33.80% | |
33.56% | |
34.33% | |
|
遞延所得稅和其他資產 |
20.60% | |
20.67% | |
20.22% | |
10.77% | |
10.48% | |
10.33% | |
9.69% | |
9.05% | |
8.87% | |
8.71% | |
8.10% | |
7.37% | |
7.22% | |
7.44% | |
6.93% | |
5.49% | |
5.26% | |
5.14% | |
5.14% | |
5.34% | |
5.19% | |
5.08% | |
|
長期資產 |
70.87% |
|
71.57% |
|
70.94% |
|
67.99% |
|
68.34% |
|
69.12% |
|
69.04% |
|
68.56% |
|
67.96% |
|
66.97% |
|
66.11% |
|
65.87% |
|
66.37% |
|
68.34% |
|
67.77% |
|
68.17% |
|
69.12% |
|
70.03% |
|
71.82% |
|
74.81% |
|
74.96% |
|
76.79% |
|
|
總資產 |
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
100.00% |
|
根據報告:
10-Q (報告日期: 2025-06-30), 10-Q (報告日期: 2025-03-31), 10-K (報告日期: 2024-12-31), 10-Q (報告日期: 2024-09-30), 10-Q (報告日期: 2024-06-30), 10-Q (報告日期: 2024-03-31), 10-K (報告日期: 2023-12-31), 10-Q (報告日期: 2023-09-30), 10-Q (報告日期: 2023-06-30), 10-Q (報告日期: 2023-03-31), 10-K (報告日期: 2022-12-31), 10-Q (報告日期: 2022-09-30), 10-Q (報告日期: 2022-06-30), 10-Q (報告日期: 2022-03-31), 10-K (報告日期: 2021-12-31), 10-Q (報告日期: 2021-09-30), 10-Q (報告日期: 2021-06-30), 10-Q (報告日期: 2021-03-31), 10-K (報告日期: 2020-12-31), 10-Q (報告日期: 2020-09-30), 10-Q (報告日期: 2020-06-30), 10-Q (報告日期: 2020-03-31).
自2020年第一季以來,Abbott Laboratories的現金與現金等價物在總資產中所佔比例呈現逐步上升的趨勢,從5.06%增加至2024年6月的約10.16%。此一升高趨勢顯示該公司在持有現金資產方面逐步擴增,可能反映出公司積累流動性以應對未來投資或可能的資本運作需求。
短期投資佔比雖有波動,但整體相對穩定於約0.3%至0.6%範圍,並未呈現明顯成長或縮減趨勢,表明公司並未大規模增加短期投資,可能偏向於維持較低流動性或短期資產配置策略。
貿易應收賬款(扣除備抵)在總資產中比例略微增加,從7.92%逐步上升至約9.49%,反映出公司在應收賬款方面的持有量略微攀升,可能與銷售規模的變動或信用政策調整相關。整體而言,此一項目前仍處於穩定範圍內,未顯示嚴重壓力或流動性風險升高。
存貨項目占比在約4%至9%之間波動,尤其在2020年和2022年期間較高,顯示公司在特定時點積累較多存貨,可能是為應對市場需求變化或供應鏈策略調整。整體存貨比例保持在合理區間,未見暴增跡象。
流動資產(包括現金、短期投資、應收款項、預付費用等)佔比有逐步上升的趨勢,由23.21%增加到約33.63%,顯示公司逐漸增加流動資源的比重,以提升短期償付與營運彈性。
長期資產的比重則呈現逐步攀升的趨勢,從約76.79%升高到約71.57%(數據中可能存在表達誤差,但整體趨勢為增加),反映公司在固定資產與長期投資上的持續投資,亦顯示資產結構逐步傾向於長期化與資本密集型的資產配置。
不動產與設備的比例在約25%至30%之間逐漸上升,顯示公司持續投入於固定資產之中,並在折舊累計方面經過長時間的累積,該項的淨值逐漸增加,代表長期資產的價值正在穩健成長中。
無形資產(扣除攤銷後)的比例則持續下降,從24.36%降至約7.05%,暗示公司在過去數年可能進行了資產重估或攤銷,或是在無形資產上有所減少,反映公司對知識產權或商譽的持有有所調整。
善意估值在整體資產中的比例約在28%至32%之間,稍有波動但大致保持穩定,代表公司在收購或合併中的商譽資產維持一定水準,並未出現大幅波動顯示資產價值的異常變動。
遞延所得稅及其他資產比例在逐漸上升,尤其在2022年後顯著增加,於2024年達到約20.6%,可能反映公司在未來稅務策略或估計中的調整,亦或是遞延所得稅資產逐步累積,提升資產整體的長期價值。
整體來看,Abbott Laboratories的資產結構呈現由較大比例的長期資產逐步微調為具有較高流動性與長期資產之間的平衡,顯示公司在提升短期流動性之餘,仍維持對長期資產的持續投資,並調整無形資產與善意等項目的比重,以適應其戰略發展及財務健康的需求。